Literature DB >> 4052139

New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity.

F Makovec, R Chistè, M Bani, M A Pacini, I Setnikar, L A Rovati.   

Abstract

New glutaramic acid derivatives were evaluated for anti-cholecystokinin (CCK) activity in vitro on guinea pig gallbladder. The compounds are competitive and specific CCK-antagonists, causing a parallel right shift of the cumulative dose-response curve of the agonist. The affinity for the binding site of the CCK-receptor for some of these compounds was hundreds of times higher than that of pro-glumide, the model compound.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4052139

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN： 0004-4172


  31 in total

1.  Effect of loxiglumide (CR-1505) on bombesin- and meal-stimulated plasma cholecystokinin in man.

Authors:  J B Jansen; M C Jebbink; B R Douglas; C B Lamers
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

Authors:  J G Csernansky; S Glick; J Mellentin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

3.  Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.

Authors:  C Niederau; R A Liddle; J A Williams; J H Grendell
Journal:  Gut       Date:  1987       Impact factor: 23.059

Review 4.  Perspectives of CCK antagonists in pancreatic research and clinical use. Part I.

Authors:  L C Rovati
Journal:  Int J Pancreatol       Date:  1991-04

5.  Role of secretin and cholecystokinin in oleic acid-stimulated pancreatic secretion in rats.

Authors:  K Shiratori; S Watanabe; T Takeuchi; K Shimizu; Y Moriyoshi
Journal:  Gastroenterol Jpn       Date:  1990-02

6.  Effect of cholestyramine and cholecystokinin receptor antagonist CR1505 (loxiglumide) on lower esophageal sphincter pressure in man.

Authors:  A A Masclee; J B Jansen; L C Rovati; C B Lamers
Journal:  Dig Dis Sci       Date:  1993-10       Impact factor: 3.199

7.  Effect of a low dose of intraduodenal fat on satiety in humans: studies using the type A cholecystokinin receptor antagonist loxiglumide.

Authors:  R J Lieverse; J B Jansen; A A Masclee; L C Rovati; C B Lamers
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

8.  Effects of CCK-receptor antagonists on CCK-stimulated pepsinogen secretion and calcium increase in isolated guinea pig gastric chief cells.

Authors:  C Sakamoto; T Matozaki; H Nishisaki; Y Konda; M Nagao; O Nakano
Journal:  Dig Dis Sci       Date:  1990-07       Impact factor: 3.199

9.  CCK-receptor antagonists proglumide and loxiglumide stimulate bile flow and biliary glutathione excretion.

Authors:  K Sztefko; P Li; N Ballatori; W Y Chey
Journal:  Dig Dis Sci       Date:  1994-09       Impact factor: 3.199

10.  Characterization of a new diphenylpyrazolidinone cholecystokinin antagonist in vitro isolated rat pancreatic acini.

Authors:  T Akiyama; I Tachibana; M Otsuki
Journal:  Int J Pancreatol       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.